Half-year report · Q2

Period2025-01-01 → 2025-06-30
Filed2025-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.18T2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥2.33T2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.11T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income¥242.1bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥126.3bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax¥226.3bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥335.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥142.2bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥173.5bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥343.1bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥107.8bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥175.9bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥110.6bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥3.79Tat 2025-06-30Cons.Assets IFRS
Total assets¥3.74Tat 2024-12-31Cons.Assets IFRS
Total assets¥3.66Tat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥1.00Tat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥961.1bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥2.79Tat 2025-06-30Cons.Equity IFRS
Net assets / equity¥2.78Tat 2024-12-31Cons.Equity IFRS
Net assets / equity¥2.67Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31vCons.Equity IFRS
Equity (owners)¥2.72Tat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.73Tat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.62Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.1bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥426.2bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥485.9bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥212.7bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥354.6bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥133.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥130.9bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥265.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥159.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥85.4bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥189.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥26.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥326.122025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥633.762024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥198.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
Equity ratio71.8%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.1%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.6%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2025-01-01 → 2025-06-30¥56.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2025-01-01 → 2025-06-30¥55.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2025-01-01 → 2025-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2025-01-01 → 2025-06-30¥5.0bn
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥27.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2025-01-01 → 2025-06-30¥15.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2025-01-01 → 2025-06-30¥15.8bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥9m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2025-01-01 → 2025-06-30¥12.9bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥276.1bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥276.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥19m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥36.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2025-01-01 → 2025-06-30¥833.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2025-01-01 → 2025-06-30¥833.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2025-01-01 → 2025-06-30¥215.4bn
—segment totalrevenue2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue external2025-01-01 → 2025-06-30¥1.18T
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥1.7bn
—segment totalsegment profit2025-01-01 → 2025-06-30¥269.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥56.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥54.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30¥4.8bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥24.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥3m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-06-30¥12.3bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥15m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥37.3bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥96.0bn
—segment totalrevenue2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue external2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
—segment totalsegment profit2024-01-01 → 2024-06-30¥150.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 782
ItemContextValueUnit
Dividends ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-32225000000JPY
Dividends ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-1779000000JPY
Dividends ss IFRSCurrentYTDDuration-34005000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember594000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration594000000JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember19977000000JPY
Acquisition of subsidiaries ss IFRSCurrentYTDDuration19977000000JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Transfer from retained earnings to capital surplus ss IFRSCurrentYTDDuration-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-6299000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration-JPY
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-6299000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-101727000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember18197000000JPY
Total transactions with owners IFRSCurrentYTDDuration-83529000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember214855000000JPY
Equity IFRSCurrentQuarterInstant_EffectivePortionOfCashFlowHedgesIFRSMember27000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember247113000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember2722396000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember64277000000JPY
Equity IFRSCurrentQuarterInstant2786674000000JPY
Profit loss before tax IFRSPrior1YTDDuration142195000000JPY
Profit loss before tax IFRSCurrentYTDDuration226343000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration53402000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration55158000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration104076000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration531000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-18575000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-18760000000JPY
Finance income ope cf IFRSPrior1YTDDuration-20581000000JPY
Finance income ope cf IFRSCurrentYTDDuration-7702000000JPY
Finance costs ope cf IFRSPrior1YTDDuration4665000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass